Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Leukemia. 2019 Aug 19;34(1):210–223. doi: 10.1038/s41375-019-0540-7

Figure 2. Enhanced loading efficiency of heteroclitic BCMA72-80 peptide encapsulated nanoparticles by immature dendritic cells.

Figure 2.

Figure 2.

Figure 2.

A: Representative flow cytometric analyses of time-dependent (0.5 - 2 hours) uptake of BCMA peptide-FITC by immature dendritic cells, as (1) free peptide, (2) encapsulated in PLGA, or (3) encapsulated in liposome. B: A summary of three independent flow cytometric analyses (N=3), showing time-dependent (1 - 18 hours) uptake of BCMA peptide-FITC by immature dendritic cells, as (1) free peptide, (2) encapsulated in PLGA, or (3) encapsulated in liposome. C: Representative confocal microscopic analyses of (1) immature dendritic cells alone (no peptide pulsed), (2) immature dendritic cells pulsed with BCMA peptide-FITC, or (3) immature dendritic cells pulsed with BCMA peptide-FITC encapsulated PLGA nanoparticles after pulsing for 18 hours.